Table 1.

CIPN clinical presentation for the different drug classes.

Drug Class	Clinical Presentation
Platinum drugs—cisplatin and carboplatin	Distal, symmetric, upper- and lower limb impairment/loss of all sensory modalities. Sensory ataxia and gait imbalance are frequent. Early reduction/loss of DTR. Coasting phenomenon. Carboplatin-related CIPN is usually milder.
Platinum drugs—oxaliplatin (acute)	Lasting 24–72 h after each administration. Cold-induced transient paresthesia at limb extremities, head and neck region (e.g., mouth, pharynx). Cramps/muscle spasm in throat muscle, jaw spasm, fasciculations
Platinum drugs—oxaliplatin (chronic)	Similar to cisplatin.
Taxanes	Distal, symmetric, upper and lower limb impairment/loss of all sensory modalities. Gait unsteadiness due to sensory ataxia. Distal, symmetric weakness in lower limbs is generally mild. Myalgia syndrome is frequent (as an atypical neuropathic pain?). Reduction/loss of DTR.
Epothilones	Similar to taxanes, but neuropathic pain is less frequent.
Vinca Alkaloids	Distal, symmetric, upper and lower limb impairment/loss of all sensory modalities. Neuropathic pain/paresthesia at limb extremities is relatively frequent. Distal, symmetric weakness in lower limbs progressing to foot drop. Autonomic symptoms (e.g., orthostatic hypotension, constipation) are more frequent than with other drug classes. Reduction/loss of DTR.
Bortezomib	Mild to moderate, distal, symmetric loss of all sensory modalities occurs. Neuropathic pain is frequent and often even severe. Mild distal weakness in lower limbs is possible. Autonomic symptoms (e.g., orthostatic hypotension, constipation). Reduction/loss of DTR.
Thalidomide and analogues	Relatively frequent neuropathic pain at limb extremities. Mild to moderate, distal, symmetric loss of all sensory modalities. Weakness is rare. Reduction/loss of DTR. Lenalidomide and pomalidomide are associated with a less severe neurotoxicity profile. Coasting phenomenon **

DTR: deep tendon reflexes. ** Described mainly in patients treated for systemic lupus erythematosus [17,18].